Covalon to Exhibit at the World Union of Wound Healing Societies in Florence, Italy
September 26 2016 - 8:00AM
Business Wire
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV), an advanced medical technologies company, today announced
that it will be exhibiting its advanced wound care line up of
products at the 5th World Congress of the World Union of Wound
Healing Societies (“WUWHS”) to be held in Florence from the 25th to
the 29th of September. In addition to exhibiting, a total of 3
clinical and scientific posters will be presented at WUWHS which
will highlight the clinical performance of several of the Company's
proprietary products.
“The WUWHS event brings together the thought leaders from almost
every wound healing society around the world as a captive audience
for Covalon to showcase our impressive product portfolio,” said
Brian Pedlar, Chief Executive Officer of Covalon. “In addition to
the opportunity for our team to interface one on one with an
incredible collection of wound care clinicians, compelling clinical
and scientific studies that highlight the clinical advantages of
our ColActive Plus product line that was recently selected as the
exclusive advanced collagen dressing for Saudi Arabian Ministry of
Health facilities are being presented.”
WUWHS serves as a highly innovative and valuable event for
medical professionals at all levels: physicians, nurses and all
those who work in contact with skin wounds on a daily
basis. WUWHS 2016 offers an extensive scientific program
including numerous symposia, training sessions, workshops and focus
sessions with leading international experts in the field of wound
management.
“With Covalon’s ever expanding penetration into international
markets, WUWHS is a great congress for us to reach key opinion
leaders from more than 40 countries” said John R. Hands, Executive
Vice President. “From our CovaWound brand of advanced wound
management dressings to our patented ColActive bio-matrix
technology designed to heal chronic wounds on limbs that may
otherwise face amputation, Covalon’s products are gaining global
recognition as a better alternative to the legacy brands
historically used by advanced wound care clinicians.”
Covalon offers unique, patent protected infection management and
advanced wound management solutions for the wound clinician.
Covalon’s CovaWound™ and ColActive® brands when used together have
the ability to rapidly promote wound closure and healing in both
acute and chronic wounds, which has been referred to by experts as
major threat to public health and the economy.1
Visit the Covalon Technologies Ltd. booth #61 from September
25-29 at the Fortezza da Basso Congress Center, Florence,
Italy.
About Covalon
Covalon Technologies Ltd. researches, develops and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
1 Sen, C. K., Gordillo, G. M., Roy, S., Kirsner, R., Lambert,
L., Hunt, T. K., Gottrup, F., Gurtner, G. C. and Longaker, M. T.
(2009), Human skin wounds: A major and snowballing threat to public
health and the economy. Wound Repair and Regeneration, 17: 763–771.
doi:10.1111/j.1524-475X.2009.00543.x
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160926005125/en/
Covalon Technologies Ltd.Brian Pedlar, CEOEmail:
bpedlar@covalon.comPhone: 905.568.8400 x 233Toll free:
1.877.711.6055Web site: www.covalon.comTwitter: @covalon
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Apr 2023 to Apr 2024